TP53 and B-cell chronic lymphocytic leukemia: And for genetic markers of CLL cells, genomic aberrations, gene abnormalities (TP53, ATM), as well as the mutation status of the variable segments of the immunoglobulin heavy chain gene (IGHV) were demonstrated to be predictive of clinical outcome.